Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS J GEORGE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1104867365
CMS profile
321938
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,139.61

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,764.07 7
Food and Beverage $375.54 9

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $1,109.61 7
AstraZeneca Pharmaceuticals LP $1,030.00 9

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS J GEORGE

NPI 1104867365 · CMS profile ID 321938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $2,139.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $18.0012/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695910219 CMS
Merck Sharp & Dohme Corporation $44.0012/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695910225 CMS
Merck Sharp & Dohme Corporation $49.5312/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695910227 CMS
Merck Sharp & Dohme Corporation $34.9912/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695912641 CMS
Merck Sharp & Dohme Corporation $18.1612/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695910221 CMS
Merck Sharp & Dohme Corporation $194.3512/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695910223 CMS
Merck Sharp & Dohme Corporation $750.5812/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695910229 CMS
AstraZeneca Pharmaceuticals LP $32.7111/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019067 CMS
AstraZeneca Pharmaceuticals LP $281.9911/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019165 CMS
AstraZeneca Pharmaceuticals LP $115.6211/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019235 CMS
AstraZeneca Pharmaceuticals LP $19.6611/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019531 CMS
AstraZeneca Pharmaceuticals LP $13.0411/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019579 CMS
AstraZeneca Pharmaceuticals LP $9.8611/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019813 CMS
AstraZeneca Pharmaceuticals LP $47.8311/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019895 CMS
AstraZeneca Pharmaceuticals LP $18.0011/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019921 CMS
AstraZeneca Pharmaceuticals LP $491.2911/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709019979 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,139.61 16
PY2020 $806.00 2
PY2021 $5,850.00 2
PY2022 $5,602.52 7
PY2023 $299.42 5
PY2024 $1,820.00 3
PY2025 $2,260.64 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $507,584.60 83
PY2024 Recipient $2,598.05 11
PY2024 Principal investigator $596,039.96 28
PY2023 Principal investigator $1,130,234.11 90
PY2022 Principal investigator $1,675,365.46 75
PY2021 Principal investigator $2,129,940.43 124
PY2020 Principal investigator $2,169,106.03 143
PY2019 Principal investigator $2,064,075.98 203

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $111.16 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 940388583
Principal investigator 1 Merck Sharp & Dohme LLC $2,065.80 12/31/2022 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair Deficient dMMR Stage IV Colorectal Carcinoma KEYNOTE-177 No dispute reported 06/30/2026 940404603
Principal investigator 1 Merck Sharp & Dohme LLC $2,791.53 12/31/2022 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair Deficient dMMR Stage IV Colorectal Carcinoma KEYNOTE-177 No dispute reported 06/30/2026 940404605
Principal investigator 1 Merck Sharp & Dohme LLC $22,125.41 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940417339
Principal investigator 1 Merck Sharp & Dohme LLC $174,581.77 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940417379
Principal investigator 1 Merck Sharp & Dohme LLC $5,030.24 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940417527
Principal investigator 1 Genentech, Inc. $10,981.00 12/13/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 950637381
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $129,150.00 12/09/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865605
Principal investigator 1 Incyte Corporation $10,031.70 11/30/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 905234567
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $51,660.00 11/30/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865587
Principal investigator 1 Genentech, Inc. $26,565.50 11/28/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
PHASE I DOSE ESCALATION STUDY OF RO7444973 ON SOLID TUMOURS No dispute reported 06/30/2026 950638293
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $25,830.00 11/21/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865571
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,379.00 11/16/2022 Non-covered Recipient Entity
Uf Health Medical Oncology - Davis Cancer Pavilion
Phase I/IIA 2L/3L CRC MSS KRAS Nivo/MEK Combo (trametinib/Novartis) No dispute reported 06/30/2026 933191027
Principal investigator 1 Merck Sharp & Dohme LLC $83,919.70 11/16/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940417337
Principal investigator 1 TerSera Therapeutics LLC $854.10 11/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117219
Principal investigator 1 TerSera Therapeutics LLC $300.30 11/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117221
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $25,830.00 10/25/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865513
Principal investigator 1 Incyte Corporation $439.00 10/21/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 905234551
Principal investigator 1 Incyte Corporation $780.00 10/21/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 905234553
Principal investigator 1 Incyte Corporation $25.00 10/21/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 905234555
Principal investigator 1 Incyte Corporation $840.00 10/21/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 905234557
Principal investigator 1 Incyte Corporation $2,340.00 10/21/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 905234559
Principal investigator 1 Incyte Corporation $650.00 10/21/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 905234561
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $64,575.00 10/12/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865479
Principal investigator 1 Seagen Inc. $7,940.00 10/05/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915671
Principal investigator 1 Seagen Inc. $6,615.00 10/05/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915677
Principal investigator 1 Seagen Inc. $8,298.00 10/05/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915681
Principal investigator 1 Seagen Inc. $227.50 10/05/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915687
Principal investigator 1 GlaxoSmithKline, LLC. $2,161.58 09/14/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 943936253
Principal investigator 1 GlaxoSmithKline, LLC. $12,550.00 09/02/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 943936255
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $25,830.00 08/30/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924866345
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $51,660.00 08/26/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924866339
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $51,660.00 08/23/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924866305
Principal investigator 1 GlaxoSmithKline, LLC. $1,864.40 08/12/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 943936257
Principal investigator 1 Merck Sharp & Dohme LLC $3,888.00 08/10/2022 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair Deficient dMMR Stage IV Colorectal Carcinoma KEYNOTE-177 No dispute reported 06/30/2026 940404601
Principal investigator 1 Seagen Inc. $890.50 08/03/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 917915601
Principal investigator 1 TerSera Therapeutics LLC $2,509.65 07/26/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117217
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $51,660.00 07/15/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924866269
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $30,996.00 07/06/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924866245
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $51,660.00 06/27/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865795
Principal investigator 1 Seagen Inc. $5,265.00 06/22/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915459
Principal investigator 1 Seagen Inc. $1,300.00 06/22/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915475
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $46,494.00 06/13/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865733
Principal investigator 1 TerSera Therapeutics LLC $4,001.40 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117193
Principal investigator 1 TerSera Therapeutics LLC $260.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117195
Principal investigator 1 TerSera Therapeutics LLC $650.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117197
Principal investigator 1 TerSera Therapeutics LLC $65.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117199
Principal investigator 1 TerSera Therapeutics LLC $3,902.60 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117201
Principal investigator 1 TerSera Therapeutics LLC $6,890.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117203
Principal investigator 1 TerSera Therapeutics LLC $421.85 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117205
Principal investigator 1 TerSera Therapeutics LLC $3,900.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117207
Principal investigator 1 TerSera Therapeutics LLC $1,235.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117209
Principal investigator 1 TerSera Therapeutics LLC $1,430.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117211
Principal investigator 1 TerSera Therapeutics LLC $3,038.10 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117213
Principal investigator 1 TerSera Therapeutics LLC $227.50 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117215
Principal investigator 1 TerSera Therapeutics LLC $1,625.00 06/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117191
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $25,830.00 05/27/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865727
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $38,745.00 05/25/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865721
Principal investigator 1 AstraZeneca Pharmaceuticals LP $53,405.50 05/10/2022 Non-covered Recipient Entity
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT FOUNDATION, INC
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 914599239
Principal investigator 1 TerSera Therapeutics LLC $2,495.35 05/05/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117189
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $12,915.00 05/02/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865715
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,178.50 04/22/2022 Non-covered Recipient Entity
University Of Florida College Of Medicine
Ph I IIA 2L 3L CRC MSS KRAS Nivo MEK Combo trametinib Novartis No dispute reported 06/30/2026 933189093
Principal investigator 1 Seagen Inc. $899.60 04/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915465
Principal investigator 1 Seagen Inc. $5,098.72 04/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 917915471
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $38,745.00 04/05/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 924865710
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $12,915.00 03/23/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) No dispute reported 06/30/2026 924865869
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $129,150.00 03/23/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) No dispute reported 06/30/2026 924865875
Principal investigator 1 Amgen Inc. $97.50 03/22/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH
CB100 Dose Comparison Study No dispute reported 06/30/2026 942841067
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $31,014.00 02/16/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) No dispute reported 06/30/2026 924865847
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $20,676.00 02/15/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) No dispute reported 06/30/2026 924865789
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $25,830.00 02/15/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) No dispute reported 06/30/2026 924865853
Principal investigator 1 TerSera Therapeutics LLC $1,248.00 02/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 954117187
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,340.00 01/20/2022 Non-covered Recipient Entity
University Of Florida
Phase I IIA 2L 3L CRC MSS KRAS Nivo MEK Combo trametinib Novartis No dispute reported 06/30/2026 933190767
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $129,150.00 01/03/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) No dispute reported 06/30/2026 924865859
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $51,660.00 01/03/2022 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) No dispute reported 06/30/2026 924865865